ELECTROPHYSIOLOGY
Risk of proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study
A multivariate analysis
Elizabeth S. Kaufman, MD, FACC*,*,
Paul A. Zimmermann, MD, FACC ,
Ted Wang, MD, FACC ,
George W. Dennish, III, MD, FACC ,
Patrick D. Barrell, BS||,
Mary L. Chandler, MD, FACOG||,
H. Leon Greene, MD, FACC|| AFFIRM Investigators
* MetroHealth Campus of Case Western Reserve University, Cleveland, Ohio, USA
South Carolina Heart Center, Columbia, South Carolina, USA
Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA
Scripps Memorial Hospital, La Jolla, California, USA
|| Axio Research Corporation, Seattle, Washington, USA
Manuscript received March 22, 2004;
revised manuscript received June 5, 2004,
accepted June 14, 2004.
* Reprint requests and correspondence: Dr. Elizabeth S. Kaufman, Heart and Vascular Research Center, Hamann 3rd Floor, MetroHealth Campus, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, Ohio 44109-1998 (Email: ekaufman{at}metrohealth.org).
OBJECTIVES: This study examined the risk of proarrhythmic events in patients receiving antiarrhythmic drugs for treatment of atrial fibrillation (AF) according to present-day safety guidelines.
BACKGROUND: Advances in understanding the proarrhythmic risk of antiarrhythmic drugs has led to development of safety guidelines for these agents. Such guidelines were used in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
METHODS: This study was an analysis of the risk of arrhythmic events (arrhythmic death, resuscitated cardiac arrest, sustained ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of the AFFIRM study. Each time an antiarrhythmic drug was begun, it was counted as an exposure to that drug and the risk of an arrhythmic event was calculated.
RESULTS: A total of 2,033 patients received 3,030 exposures to antiarrhythmic drugs. Ninety-six arrhythmic events occurred by six years. Patients with a left ventricular ejection fraction <40% had more arrhythmic events. Twelve documented cases of torsade de pointes VT were noted. The incidence of torsade de pointes was 0.6% at five years (95% confidence interval 0.32 to 1.07).
CONCLUSIONS: The overall risk of adverse arrhythmic events upon exposure to antiarrhythmic drugs in the AFFIRM study was reasonably low. Strict criteria for the safe use of antiarrhythmic drugs were successful in minimizing proarrhythmic events.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | AFFIRM = Atrial Fibrillation Follow-up Investigation of Rhythm Management | | CI = confidence interval | | LV = left ventricular | | VT = ventricular tachycardia |
|
This article has been cited by other articles:
|
|
|
|
 
S. Singla, P. Karam, A. J. Deshmukh, J. Mehta, and H. Paydak
Review of Contemporary Antiarrhythmic Drug Therapy for Maintenance of Sinus Rhythm in Atrial Fibrillation
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2012;
17(1):
12 - 20.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Zimetbaum
Antiarrhythmic Drug Therapy for Atrial Fibrillation
Circulation,
January 17, 2012;
125(2):
381 - 389.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Markowitz
Rhythm Control for Atrial Fibrillation: Favorable Outcomes or Futile Endeavor?
J. Am. Coll. Cardiol.,
November 1, 2011;
58(19):
1986 - 1988.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-M. Cha, A. Wokhlu, S. J. Asirvatham, W.-K. Shen, P. A. Friedman, T. M. Munger, J. K. Oh, K. H. Monahan, J. M. Haroldson, D. O. Hodge, et al.
Success of Ablation for Atrial Fibrillation in Isolated Left Ventricular Diastolic Dysfunction: A Comparison to Systolic Dysfunction and Normal Ventricular Function
Circ Arrhythm Electrophysiol,
October 1, 2011;
4(5):
724 - 732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Andersen, M. L. Hansen, G. H. Gislason, T. K. Schramm, F. Folke, E. Fosbol, S. Z. Abildstrom, M. Madsen, L. Kober, and C. Torp-Pedersen
Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study
Europace,
July 1, 2009;
11(7):
886 - 891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-Y. Le Heuzey
The risk of antiarrhythmic drugs in atrial fibrillation: 20 years of controversies
Europace,
July 1, 2009;
11(7):
840 - 841.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Eckart and L. M. Epstein
Interventional Therapy for Atrial and Ventricular Arrhythmias
Card. Surg. Adult,
January 1, 2008;
3(2008):
1357 - 1374.
[Full Text]
|
|
|
|
|
|
|
M. E.W. Hemels, A. C.P. Wiesfeld, D. J. Van Veldhuisen, M. P. Van den Berg, and I. C. Van Gelder
Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular function
Europace,
April 1, 2007;
9(4):
239 - 245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rienstra, D. J. Van Veldhuisen, V. E. Hagens, A. V. Ranchor, N. J.G.M. Veeger, H. J.G.M. Crijns, I. C. Van Gelder, and for the RACE Investigators
Gender-Related Differences in Rhythm Control Treatment in Persistent Atrial Fibrillation: Data of the Rate Control Versus Electrical Cardioversion (RACE) Study
J. Am. Coll. Cardiol.,
October 4, 2005;
46(7):
1298 - 1306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Goldman and L. B. Croft
Atrial Fibrillation: The Ancient Conundrum Defies Simple Solution
J. Am. Coll. Cardiol.,
June 7, 2005;
45(11):
1813 - 1814.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Low Proarrhythmia Risk in Treated Afib Patients
Journal Watch Cardiology,
November 26, 2004;
2004(1126):
2 - 2.
[Full Text]
|
|
|
|
